CIMA rejects Cephalon bid

08 Sep 2003
News

Executive Summary

Cephalon's proposal to acquire CIMA at $26 per share does not represent a superior offer to CIMA's proposed merger with aaiPharma, CIMA says Sept. 2. Company received unsolicited takeover bid from Cephalon following announcement of proposed merger with aaiPharma; CIMA was prohibited from entering negotiations with Cephalon unless its board deemed the offer superior to merger plans (1"The Pink Sheet" Aug. 25, 2003, p. 17)...

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS042417

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS042417

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

CIMA rejects Cephalon bid

News

Executive Summary

Related Content

CIMA negotiations with Cephalon

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert